319 related articles for article (PubMed ID: 9267790)
1. Innovative approaches to the hormonal treatment of advanced prostate cancer.
Trachtenberg J
Eur Urol; 1997; 32 Suppl 3():78-80. PubMed ID: 9267790
[TBL] [Abstract][Full Text] [Related]
2. Endocrine therapy: where do we stand and where are we going?
Schröder FH
Cancer Surv; 1991; 11():177-94. PubMed ID: 1841751
[TBL] [Abstract][Full Text] [Related]
3. Endocrine therapy for prostate cancer.
Labrie F
Endocrinol Metab Clin North Am; 1991 Dec; 20(4):845-72. PubMed ID: 1778180
[TBL] [Abstract][Full Text] [Related]
4. [New approach in the treatment of prostatic cancer: combined use of a LHRH agonist and an androgen antagonist].
Labrie F; Dupont A; Belanger A; Lefebvre FA; Raynaud JP
J Pharmacol; 1983; 14 Suppl 3():117-35. PubMed ID: 6423907
[TBL] [Abstract][Full Text] [Related]
5. Hormonal therapy for locally advanced prostate cancer.
Einstein AB
NCI Monogr; 1988; (7):171-4. PubMed ID: 3050536
[TBL] [Abstract][Full Text] [Related]
6. [Possibilities in drug therapy in prostatic carcinoma].
Schmid HP
Ther Umsch; 1995 Jun; 52(6):418-22. PubMed ID: 7541571
[TBL] [Abstract][Full Text] [Related]
7. [Prostate cancer--treatment of hormone independent cancer].
Yamanaka H; Imai K; Suzuki T; Masimo T
Gan To Kagaku Ryoho; 1991 Nov; 18(14):2390-5. PubMed ID: 1719940
[TBL] [Abstract][Full Text] [Related]
8. Overview of enzyme inhibitors and anti-androgens in prostatic cancer.
Geller J
J Androl; 1991; 12(6):364-71. PubMed ID: 1769904
[TBL] [Abstract][Full Text] [Related]
9. Beneficial effects of androgen-primed chemotherapy in the Dunning R3327 G model of prostatic cancer.
English HF; Heitjan DF; Lancaster S; Santen RJ
Cancer Res; 1991 Apr; 51(7):1760-5. PubMed ID: 2004359
[TBL] [Abstract][Full Text] [Related]
10. Chlormadinone acetate withdrawal syndrome under combined androgen blockade for advanced prostate cancer.
Sekido N; Kawai K; Akaza H; Koiso K
Jpn J Clin Oncol; 1995 Aug; 25(4):164-7. PubMed ID: 7545251
[TBL] [Abstract][Full Text] [Related]
11. Dihydrotestosterone concentration in prostate cancer tissue as a predictor of tumor differentiation and hormonal dependency.
Geller J; Albert J; de la Vega D; Loza D; Stoeltzing W
Cancer Res; 1978 Nov; 38(11 Pt 2):4349-52. PubMed ID: 81107
[TBL] [Abstract][Full Text] [Related]
12. Relationship between tumor size and curability of prostatic cancer by combined chemo-hormonal therapy in rats.
Isaacs JT
Cancer Res; 1989 Nov; 49(22):6290-4. PubMed ID: 2804976
[TBL] [Abstract][Full Text] [Related]
13. Rationale for blockade of adrenal as well as testicular androgens in the treatment of advanced prostate cancer.
Geller J
Semin Oncol; 1985 Mar; 12(1 Suppl 1):28-35. PubMed ID: 3883502
[TBL] [Abstract][Full Text] [Related]
14. Use of the nonsteroidal anti-androgen Casodex in advanced prostatic carcinoma.
Kennealey GT; Furr BJ
Urol Clin North Am; 1991 Feb; 18(1):99-110. PubMed ID: 1992575
[TBL] [Abstract][Full Text] [Related]
15. Science behind total androgen blockade: from gene to combination therapy.
Labrie F; Bélanger A; Dupont A; Luu-The V; Simard J; Labrie C
Clin Invest Med; 1993 Dec; 16(6):475-92. PubMed ID: 8013153
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological studies on androgen suppression in therapy of prostate carcinoma.
Sandow J; von Rechenberg W; Engelbart K
Am J Clin Oncol; 1988; 11 Suppl 1():S6-10. PubMed ID: 3291602
[TBL] [Abstract][Full Text] [Related]
17. Total androgen ablation: American experience.
Crawford ED; Nabors WL
Urol Clin North Am; 1991 Feb; 18(1):55-63. PubMed ID: 1899495
[TBL] [Abstract][Full Text] [Related]
18. Medical management of prostatic diseases.
Schlegel PN
Adv Intern Med; 1994; 39():569-601. PubMed ID: 7511322
[TBL] [Abstract][Full Text] [Related]
19. [Theoretical considerations and initial clinical results of intermittent hormone treatment of patients with advanced prostatic carcinoma].
Bruchovsky N; Goldenberg SL; Rennie PS; Gleave M
Urologe A; 1995 Sep; 34(5):389-92. PubMed ID: 7483155
[TBL] [Abstract][Full Text] [Related]
20. Controversies in the treatment of prostate cancer with maximal androgen deprivation.
McLeod DG; Moul JW
Surg Oncol Clin N Am; 1995 Apr; 4(2):345-59. PubMed ID: 7796290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
